e-learning
resources
Copenhagen 2005
Tuesday 20.09.2005
Treatment of pulmonary arterial hypertension
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Effects of sildenafil on 6-minute walk distance (6MWD) and WHO functional class (FC) in pulmonary arterial hypertension (PAH) patients after 1 year of treatment
O. Sitbon, G. Burgess, T. Parpia, H. Ghofrani (Clamart, France; Sandwich, United Kingdom; Giessen, Germany)
Source:
Annual Congress 2005 - Treatment of pulmonary arterial hypertension
Session:
Treatment of pulmonary arterial hypertension
Session type:
Oral Presentation
Number:
3129
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
O. Sitbon, G. Burgess, T. Parpia, H. Ghofrani (Clamart, France; Sandwich, United Kingdom; Giessen, Germany). Effects of sildenafil on 6-minute walk distance (6MWD) and WHO functional class (FC) in pulmonary arterial hypertension (PAH) patients after 1 year of treatment. Eur Respir J 2005; 26: Suppl. 49, 3129
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Is 6-minute walk distance (6MWD) associated with long-term outcomes in pulmonary arterial hypertension (PAH)? Results from SERAPHIN
Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment
Year: 2013
The role of per cent predicted 6-min walk distance in pulmonary arterial hypertension
Source: Eur Respir J 2010; 36: 1294-1301
Year: 2010
Change in 6 minute walk distance (6MWD) following a familiarisation test and exercise training in patients with chronic obstructive pulmonary disease (COPD): influence of disability
Source: Annual Congress 2008 - Rehabilitation and influencing factors
Year: 2008
Role of exercise cardiac index to predict NYHA functional class, 6-minute walk test distance and survival in idiopathic, heritable and anorexigen-associated pulmonary arterial hypertension
Source: Annual Congress 2011 - Physiology of human pulmonary hypertension
Year: 2011
Exercise testing to predict outcome in idiopathic versus associated pulmonary arterial hypertension
Source: Eur Respir J 2012; 40: 1410-1419
Year: 2012
Glucocorticosteroid reversibility testing with oral prednisone (²steroid trial²) for 4 weeks: time-response study using serial spirometry and 6-minute walk distance (6MWD) in patients with moderate to severe stable COPD
Source: Eur Respir J 2004; 24: Suppl. 48, 429s
Year: 2004
Analysis of oxygen saturation (O2 sat.) During the six minutes walk distance (6MWD) test in chronic obstructive pulmonary disease (COPD) patients
Source: Annual Congress 2009 - Gas exchange and exercise in respiratory diseases
Year: 2009
Improvement of 6-minutes walking test (6MWT) and pulmonary functional status after an inpatient pulmonary rehabilitation program (PRP) in moderate-severe and severe COPD patients
Source: Eur Respir J 2004; 24: Suppl. 48, 244s
Year: 2004
Degree of exercise limitation in COPD: impact on 6 minute walk (6MW) in response to long-acting β-agonist (LABA) treatment
Source: Eur Respir J 2007; 30: Suppl. 51, 76s
Year: 2007
Clinical significance of falling oxygen saturation per walking distance (ΔSaO2/6MWD) during six minute walk test (6MWT) in idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2015 – IPF: clinical aspects
Year: 2015
The six minute walk test (6MWT) can predict O
2
flows required to prevent exercise induced O
2
desaturation in patients with idiopathic pulmonary fibrosis
Source: Annual Congress 2010 - Clinical issues in idiopathic pulmonary fibrosis
Year: 2010
Is a double 6-minute walk test (6MWT) required as part of the routine assessment of pulmonary rehabilitation (PR) in COPD patients?
Source: International Congress 2014 – Physical activity, exercise and physiotherapy in patients with COPD
Year: 2014
The influence of O
2
on exercise capacity (6-minute-walking-distance, 6MWD) in COPD
Source: Annual Congress 2011 - Measuring physical activity and exercise performance in chronic lung disease: implications for rehabilitation
Year: 2011
Tadalafil improves exercise capacity and delays time to clinical worsening in patients with pulmonary arterial hypertension (PAH)
Source: Annual Congress 2008 - Medical treatment of pulmonary hypertension
Year: 2008
Interpretation of treatment changes in 6-minute walk distance in patients with COPD
Source: Eur Respir J 2008; 32: 637-643
Year: 2008
6MWD in patients with pulmonary arterial hypertension (PAH)
Source: Eur Respir J 2003; 22: Suppl. 45, 464s
Year: 2003
The 6-min walk distance: change over time and value as a predictor of survival in severe COPD
Source: Eur Respir J 2004; 23: 28-33
Year: 2004
The use test valsalva manoevre (VM) in diagnosis pulmonary hypertension (PH) for early rehabilitation of patients with lung sarcoidosis (LS)
Source: Eur Respir J 2006; 28: Suppl. 50, 72s
Year: 2006
Effect of continued pirfenidone treatment following a ≥ 15% decline in 6-minute walk distance (6MWD) in patients with idiopathic pulmonary fibrosis (IPF): Pooled analysis from 3 pivotal studies
Source: International Congress 2016 – New and old therapies for chronic lung diseases
Year: 2016
Heart rate responses during the 6-minute walk test in pulmonary arterial hypertension
Source: Eur Respir J 2006; 27: 114-120
Year: 2006
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept